CITF Research Results

CITF Research Results2021-05-12T10:36:38-04:00

Studies being launched to support vaccine effectiveness and safety monitoring across Canada

A consortium of Canadian organizations, including the Public Health Agency of Canada (PHAC), the Canadian Research Immunization Network (CIRN), the National Advisory Committee on Immunization (NACI) and the CITF, are collaborating through the Vaccine Surveillance Reference group (VSRG) to identify new studies to support comprehensive vaccine effectiveness and safety monitoring efforts across Canada.

Explore the latest seroprevalence results in Canada via SeroTracker

SeroTracker is an online tool that tracks and visualizes global COVID-19 serology testing data – testing that examines blood samples for antibodies that indicate a person has been exposed to the novel coronavirus. SeroTracker was initiated in early April 2020 to serve the COVID-19 Immunity Task Force’s need for global serological testing data as well as creating a dashboard focused on Canadian seroprevalence studies. [...]

May 11, 2021|Seroprevalence studies|

Most Montreal parents willing to vaccinate their children, but vaccine hesitancy more prominent among visible minorities

Health Canada approved the use of Pfizer-BioNTech’s COVID-19 vaccine on children 12 and older on May 5, 2021. As part of her CITF-funded research, Dr. Kate Zinszer, from Université de Montréal, and her colleagues examined willingness to vaccinate children according to level of education, neighbourhood, and visible minority status within a cohort of parents in Montreal. In a preprint, therefore not yet peer-reviewed, most [...]

May 11, 2021|Vaccine surveillance studies|

Recovered COVID-19 individuals can have SARS-CoV-2 antibodies for at least 6 months

In a recent publication in Viruses, Dr. Ishac Nazy from McMaster University finds that SARS-CoV-2 antibodies against the spike and receptor binding domain are present for at least six months, confirming similar research by other CITF-funded researchers. In this publication, Dr. Nazy characterizes SARS-CoV-2 antibodies in recovered COVID-19 patients. This study was funded in part by the COVID-19 Immunity Task Force, in collaboration with [...]

May 4, 2021|Immune mechanism studies|

Changes in immune cells in COVID patients could be a sign suggesting an unfavorable outcome

In a publication in the Journal of Clinical Investigation, Drs. Daniel Kaufmann and Andrés Finzi from Université de Montréal and collaborators, found that patients with acute SARS-CoV-2 infection have altered immune responses affecting the severity of symptoms and mortality. These findings may help clinicians identify patients at risk of unfavourable outcomes and shed light on what new therapies could seek to target. This study [...]

April 27, 2021|Immune mechanism studies|

T cell responses are also important in immunity against SARS-CoV-2

The 20 Most-Read Articles in March 2021 Their article was read over 1300 times in the last 5 months   While many agree on the importance of antibodies in SARS-CoV-2 infection, T cells have also taken the spotlight as a key contributor to immunity. Published in The Journal of Immunology, Drs. Tania Watts and Mario Ostrowski, from University of Toronto, found that SARS-CoV-2 recovered [...]

April 27, 2021|Immune mechanism studies|

Latest Canadian findings point to widening inequalities in the fight against COVID-19

Serosurveillance survey shows SARS-CoV-2 infections growing much faster in poorer neighbourhoods and amongst racialized populations Results from the latest Canadian Blood Services/COVID-19 Immunity Task Force (CITF) collaborative nine-province seroprevalence study confirm that the pandemic is increasingly affecting poorer neighbourhoods and racialized populations. The inequalities in risk in getting COVID-19 were identified early in the pandemic and were the focus of the Chief Public Health Officer’s [...]

April 20, 2021|Seroprevalence studies|

Dried Blood Spot Assays: A Review

Many Canadian serosurveys have opted to use dried blood spot (DBS) tests as a practical means to study population-level SARS-CoV-2 prevalence. Tens of thousands of Canadians have received DBS kits in the mail. In this preprint, not yet peer-reviewed, researchers, including several CITF members, set out to determine which of the available DBS assays performed the best. This research was partially funded by the [...]

Go to Top